Menu

Recent Interviews

Dirk Graszt, CEO, Clean Logistics SE

Dirk Graszt
CEO | Clean Logistics SE
Trettaustr.32, 21107 Hamburg (DE)

info@cleanlogistics.de

+49-4171-6791300

Interview Clean Logistics: Hydrogen challenge to Daimler + Co.


Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


24. April 2020 | 07:36 CET

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

  • Medical
Photo credits: pixabay.com

There are topics and products that are the focus of general interest overnight. Often these are needs or problems that require a time-critical solution. The current situation surrounding the spread of the Corona Virus COVID-19 has brought numerous companies into the focus of investors in recent weeks. The backgrounds are of a very different nature. On the one hand, there are manufacturers of masks, disinfectants or respiratory equipment, as well as medical companies that may have an active ingredient for the prevention or therapy of the Corona Virus on offer. But there are also topics that are beyond the general interest and represent a huge market.

time to read: 1 minutes by Mario Hose
ISIN: AU000000MEM5 , US09075V1026 , US3755581036


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Growing billion dollar market

The desire of couples to have children tends to occur increasingly later in modern society. Often professional or economic reasons are in the foreground before the family picture is rounded off with their own children. However, the chances of a successful natural pregnancy decrease with increasing age. Often couples with increasing frustration then consult appropriate experts to deal with the subject of artificial insemination.

Solution increases chances of success

The Australian company Memphasys has developed a product called FELIX, which separates the high-quality sperm from the man's seminal fluid and thus increases the chances of success of artificial insemination. The advantage of FELIX is that the process only takes a few minutes and the costs of treatment can be reduced. The product is to be launched in several countries in the second half of 2020. The market for artificial insemination is growing steadily and any solution that statistically increases the chances of a successful pregnancy will be in high demand.

Memphasys shares are traded in Australia and Germany and at a price of AUD 0.048 the company has a market capitalization of AUD 36 million. Further details of the FELIX launch should increase interest in Memphasys. Introduction at the right time could be worthwhile. Further information is available in the following video interview with Executive Chairman Alison Coutts: youtu.be/kHA-UhbeZH8

Success and failure

BioNTech from Germany is currently working with Pfizer on the search for a vaccine against COVID-19. The news that tests are now being carried out on 200 people in order to obtain marketing authorisation if successful, has boosted the company's share price. The valuation of BioNTech has now risen to over EUR 10 billion. However, should the success fail to materialise, the disappointment is likely to be great.

A report on Gilead Science that the drug Remdesiver did not achieve the desired success in tests in connection with the treatment of Corona patients has caused the share price to fall and the value of the company has slid back below the USD 100 billion mark. It seems that the pandemic issue will be with us for some time to come.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

09. December 2020 | 14:16 CET | by Nico Popp

Valeo Pharma, CureVac, Moderna, Sartorius: high-flyers or latecomers?

  • Medical

The pandemic continues to spread: Germany is now facing a complete lockdown. Meanwhile, there is good news from the vaccine and drug manufacturers. There are several vaccines available, and from 2021 onwards, vaccination programs are to be implemented rapidly in all industrialized countries. Nevertheless, question marks remain: How long a vaccination will protect a person remains to be seen. For this reason, drugs and other measures to treat patients successfully remain essential. One of these drugs has just received approval from the Canadian regulatory authorities.

Read

05. May 2020 | 08:33 CET | by Mario Hose

Evotec, Medigene, Memphasys - the right investment timing

  • Medical

The health sector has been in the focus of investors not only since the outbreak of the corona pandemic. The pursuit of a healthy and long life is the motivation for research and development around the globe. In addition to Europe and the USA, Australia as a continent is also a location for ideas and innovations. Investors usually always ask the same questions. How expensive and how long does it take to develop the drug or solution and how big is the market. The bigger the problem or need to be treated, the more lucrative it is.

Read

04. March 2020 | 07:27 CET | by Mario Hose

Medigene, Memphasys, Qiagen - which stocks belong in the portfolio?

  • Medical

In times of price fluctuations, so-called 'buy on dips' strategy can be an effective method of achieving a favorable entry price for listed companies. Global trends as a framework can be decisive for a successful investment decision. For a modern society, the healthcare sector has become a particularly important sector. In addition to the desire for a long life with health and care, there is also an increasing demand for products and therapies that can fulfil couples' desire to have children. There is a broad spectrum and as an investor it is worth taking a look at the companies.

Read